VistaGen Therapeutics

About:

VistaGen is a biopharmaceutical company developing innovative product candidates for patients with diseases and disorders involving the CNS.

Website: http://www.vistagen.com

Twitter/X: vistagen

Top Investors: Biotechnology Value Fund, Great Point Partners, Logos Capital, Nantahala Capital Management, Surveyor Capital

Description:

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2 development, initially for the adjunctive treatment of Major Depressive Disorder (MDD) in patients with an inadequate response to standard antidepressants.